Letters Dipeptidyl peptidase-4 inhibitors, sulphonylureas, and hypoglycaemia

Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia

BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i3186 (Published 07 June 2016) Cite this as: BMJ 2016;353:i3186
  1. Denis Boucaud-Maitre, French West Indies toxicovigilance coordinator1
  1. 1Basse-Terre Hospital, Basse-Terre, France
  1. denis.boucaud{at}gmail.com

The main eligibility criterion in Salvo and colleagues’ meta-analysis on the increased risk of hypoglycaemia was that trials studied the effect of adding one dipeptidyl peptidase-4 (DPP-4) inhibitor or placebo to sulphonylureas.1

However, it is unclear why the EXAMINE study was included in this meta-analysis.2 This trial was a cardiovascular outcome study that compared alogliptin with placebo administered in …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe